Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 1/20 | 0.35 |
| ▸ | CHRNG | P07510 | 1/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | CHRND | Q07001 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18968945 | 0.95 | CHRNB4 (0.33) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL18969002 | 0.93 | MMP12 (0.31) | — | |
| SCHEMBL18968971 | 0.92 | MMP12 (0.31) | — | |
| SCHEMBL18968974 | 0.91 | — | — | |
| SCHEMBL17827455 | 0.91 | CA12 (0.35) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL17827462 | 0.91 | CA12 (0.35) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL18968988 | 0.90 | CA12 (0.34) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL18968920 | 0.90 | CHRNB4 (0.39) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL18968919 | 0.90 | CHRNB4 (0.39) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL18969107 | 0.89 | AHR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10361374-B2 | Amine compound and organic light emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-07-23 | — | — | US | disclosed |
| US-20170170402-A1 | AMINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170170402-A1 | AMINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170170402-A1 | AMINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | AOC2, MAOA, AOC3 | CHRNA1 864/4885CHRNG 2709/4885CHRNB1 2179/4885 |
| US-10361374-B2 | Amine compound and organic light emitting device including the same | AOC2, MAOA, AOC3 | CHRNA1 864/4885CHRNG 2709/4885CHRNB1 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.